Health Industries Research (HIRC)

🔹 Join us at AMCP Nexus 2024 in Las Vegas! 🔹 From October 14-17, we’ll be connecting with industry leaders and exploring the latest innovations in managed care, pharmacy, and healthcare. If you’re interested in discussing current market trends in market access or learning more about HIRC’s offerings, we’d love to meet! Reach out via messages or email us to schedule time to connect: 📧 [Josh Mader]: jmader@hirc.om 📧 [Griffin Ernst]: gernst@hirc.com Let’s collaborate to drive healthcare innovation forward! #AMCPNexus #LasVegas #MarketAccess #ManagedCare #PharmacyCare #ValueBasedCare #HealthcareInnovation #HIRC #HealthOutcomes #AMCP2024 #PatientCenteredCare

📢 New Report Release: Rare Disease Market Insights Our latest report dives deep into the Specialty Pharmacy and Rare Disease landscape! 🧬 Discover key strategies shaping this evolving market and how pharmaceutical leaders are supporting patients with rare conditions. #HIRC #RareDisease #SpecialtyPharmacy #MarketInsights #HealthcareInnovation

🚨 New Report Alert! 🚨 We just released our latest report: IDNs, Quality, and Population Health! 🎯 Get the insights you need to understand how leading IDNs are shaping quality initiatives and driving population health outcomes. #HIRC #IDNs #PopulationHealth #HealthcareQuality #MarketInsights

Great to see the advancement and investment in the exploration of treatments for Alzheimer's

In the battle over drug prices, one sector of the healthcare industry has risen above all the players as the boogeyman: pharmacy benefit managers. In this special edition, BioSpace takes a deep dive into the lens now focused on PBMs’ business practices. #healthcare #pharma #PBMs #biospace https://hubs.li/Q02Vwyj60

There’s a new treatment option for people with certain gastric cancers after the FDA greenlit Astellas’ Vyloy on Friday. With the approval, Vyloy becomes the first claudin 18.2–targeted therapy in the U.S. for gastric or gastroesophageal junction cancer, according to Astellas. #FDA #drugapprovals #cancertreatment #biospace https://hubs.ly/Q02VhRxW0

Non-communicable diseases (NCDs) such as diabetes, cancer and cardiovascular disease kill 41 million people each year. Of these, 17 million people die from NCDs before the age of 70. 86% of these premature deaths occur in low- and middle-income countries, whose health systems are the least equipped to deliver care for chronic diseases. For the Global Week for Action on NCDs, our own Loren Becker tackles the barriers to NCD care and the importance of collective action to address systemic challenges that inhibit access to NCD care. #WeAreLilly

The regulator’s approval on Friday of Vyloy for gastric or gastroesophageal junction cancer makes it the first and only claudin 18.2-targeted therapy approved in the U.S. for these indications, according to Astellas Pharma. #cancertreatment #pharma #FDA #biospace https://hubs.li/Q02V5bRr0

BMO Capital Markets analyst Evan Seigerman in a note to investors said the late-stage data for Vertex Pharmaceuticals's experimental non-opioid pain medication “reaffirms our confidence in the strength of suzetrigine’s profile.” However, William Blair analysts view these data as “an incremental positive” as the company faces challenges in targeting the acute pain market. #investors #pharma #biospace https://hubs.li/Q02V5JJ20